Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leap In US Sales Of IUDs Linked To Trump Election, ACA Repeal Efforts

Executive Summary

Sales of contraceptive intrauterine devices rose in the 4th quarter of 2016 at some companies. The increase in interest in IUDs coincides with efforts to repeal Obamacare and eliminate contraceptive coverage guarantees, according to Planned Parenthood and AthenaHealth.

You may also be interested in...

Study: Election Of Trump Triggered 22% Spike In Birth Control Implants In US

The surprise election of Donald Trump to the nation's highest office in 2016 spurred many US women to be implanted with long-acting reversible contraceptives (LARCs), a study published Feb. 4 in JAMA Internal Medicine contends.

Kavanaugh Hearings: Dems Tell Judge Abortion Rights, Preexisting Conditions Top Their Concerns

Democrats on the Senate Judiciary Committee told Supreme Court nominee Brett Kavanaugh on the first day of confirmation hearings Tuesday they will question his rulings on abortion and women’s reproductive rights, and on retaining federal insurance coverage for people with preexisting conditions under Obamacare. As the potential conservative swing vote on the high court, Kavanaugh’s decisions can impact sales of contraceptive devices and medtech to treat heart disease, cancer, diabetes and an array of other preexisting conditions.

How Kavanaugh High Court Pick Could Increase IUD Sales

A look at what impacts a changed court could have on abortion rights, and related IUD products that device companies Bayer and Allergan make and sell, plus a peek at new contraceptive products on the horizon.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts